{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:08Z","timestamp":1787026388884,"version":"build-2736575974"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the association between metabolic syndrome (MetS) and its components and prostate cancer (PCa).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled 482 943 consecutive men who underwent routine health checkups at the Health Management Center of West China Hospital Between 2010 and 2017. For patients with elevated prostate-specific antigen (PSA) levels or color Doppler ultrasound indicating abnormal prostates, we recommended prostate puncture and follow-up. We used the chi-square test and independent t-test for categorical variables and continuous variables, respectively. We used logistic regression analysis to evaluate the effects of MetS and its components on prostate cancer risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that the incidence of PCa in Chinese men over 40 years of age was 0.1%. Among the 85882 participants, 31.5% (27016\/85882) of the patients were diagnosed with MetS. PCa was associated with older age, higher PSA levels, lighter weight and shorter height, hypertension, elevated fasting blood glucose (FBG) and HDL cholesterol level, lower triglycerides. After excluded the interference of other factors in multivariate logistic analysis, we found that MetS, hypertension, hyperlipidemia, hyperglycemia, and obesity were not related to the risk of PCa. High age and PSA levels were risk factors for prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High age and PSA levels were risk factors for prostate cancer. MetS, hypertension, hyperlipidemia, hyperglycemia, and obesity were not related to the risk of PCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.787268","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T08:30:26Z","timestamp":1653035426000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The Association Between Metabolic Syndrome and Prostate Cancer Risk: A Large-Scale Investigation and Study of Chinese"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoshuai","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruicen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huairong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global Cancer Statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.02.054","article-title":"International Variation in Prostate Cancer Incidence and Mortality Rates","volume":"61","author":"Center","year":"2012","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.109.192644","article-title":"Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.eururo.2014.01.040","article-title":"Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort","volume":"67","author":"Bhindi","year":"2015","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000169490.78443.59","article-title":"Hypogonadism and Metabolic Syndrome: Implications for Testosterone Therapy","volume":"174","author":"Makhsida","year":"2005","journal-title":"J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.554078","article-title":"Endocrinology of the Aging Prostate: Current Concepts","volume":"12","author":"Cannarella","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj284","article-title":"Metabolic Syndrome Predicts Prostate Cancer in a Cohort of Middle-Aged Norwegian Men Followed for 27 Years","volume":"164","author":"Lund Haheim","year":"2006","journal-title":"Am J Epidemiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2015.04.006","article-title":"The Metabolic Syndrome and Cancer: Is the Metabolic Syndrome Useful for Predicting Cancer Risk Above and Beyond Its Individual Components","volume":"41","author":"Harding","year":"2015","journal-title":"Diabetes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj320","article-title":"The Metabolic Syndrome Is Associated With Reduced Risk of Prostate Cancer","volume":"164","author":"Tande","year":"2006","journal-title":"Am J Epidemiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/bf03346748","article-title":"Effect of Metabolic Syndrome and Its Components on Prostate Cancer Risk: Meta-Analysis","volume":"36","author":"Esposito","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2017.1","article-title":"Meta-Analysis of Metabolic Syndrome and Prostate Cancer","volume":"20","author":"Gacci","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2010.00078.x","article-title":"Prevalence and Correlates of Metabolic Syndrome Based on a Harmonious Definition Among Adults in the US","volume":"2","author":"Ford","year":"2010","journal-title":"J Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.07.022","article-title":"The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) Prevalence of the Metabolic Syndrome in a Chinese Population","volume":"67","author":"Thomas","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0b013e31828ce95d","article-title":"Metabolic Syndrome and Postmenopausal Breast Cancer: Systematic Review and Meta-Analysis","volume":"20","author":"Esposito","year":"2013","journal-title":"Menopause"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-012-0096-6","article-title":"Prospective Cohort Study of Metabolic Risk Factors and Gastric Adenocarcinoma Risk in the Metabolic Syndrome and Cancer Project (Me-Can)","volume":"24","author":"Lindkvist","year":"2013","journal-title":"Cancer Causes Control"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-10-0112","article-title":"The Metabolic Syndrome and the Risk of Prostate Cancer Under Competing Risks of Death From Other Causes","volume":"19","author":"Grundmark","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.1646.13.10","article-title":"Metabolic Syndrome and the Risk of Prostate Cancer in Finnish Men: A Population-Based Study","volume":"13","author":"Laukkanen","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11406.x","article-title":"Metabolic Syndrome Increases the Risk of Aggressive Prostate Cancer Detection","volume":"111","author":"Morote","year":"2013","journal-title":"BJU Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.03.013","article-title":"Racial Differences in Risk of Prostate Cancer Associated With Metabolic Syndrome","volume":"74","author":"Beebe-Dimmer","year":"2009","journal-title":"Urology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682x.148138","article-title":"The Association Between Metabolic Syndrome and Advanced Prostate Cancer in Chinese Patients Receiving Radical Prostatectomy","volume":"17","author":"Zhang","year":"2015","journal-title":"Asian J Androl"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2004.01.005","article-title":"Insulin-Like Growth Factor-I and Cancer Risk","volume":"14","author":"Ibrahim","year":"2004","journal-title":"Growth Horm IGF Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","article-title":"Prostate Cancer and Inflammation: The Evidence","volume":"60","author":"Sfanos","year":"2012","journal-title":"Histopathology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12843","article-title":"Metabolic Syndrome-Like Components and Prostate Cancer Risk: Results From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Study","volume":"115","author":"Sourbeer","year":"2015","journal-title":"BJU Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/me.2013-1039","article-title":"Minireview: The Molecular and Genomic Basis for Prostate Cancer Health Disparities","volume":"27","author":"Powell","year":"2013","journal-title":"Mol Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.787268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T14:39:17Z","timestamp":1675607957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.787268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":24,"alternative-id":["10.3389\/fendo.2022.787268"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.787268","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"article-number":"787268"}}